Suppr超能文献

代谢型谷氨酸受体1(Grm1)在黑素细胞转化中的致癌活性。

Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.

作者信息

Shin Seung-Shick, Namkoong Jin, Wall Brian A, Gleason Ryan, Lee Hwa Jin, Chen Suzie

机构信息

Department of Chemical Biology, Ernest Mario School of Pharmacy, Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, Piscataway, NJ, USA.

出版信息

Pigment Cell Melanoma Res. 2008 Jun;21(3):368-78. doi: 10.1111/j.1755-148X.2008.00452.x. Epub 2008 Apr 23.

Abstract

Previously, we reported a transgenic mouse line, TG-3, that develops spontaneous melanoma with 100% penetrance. We demonstrated that ectopic expression of Grm1 in melanocytes was sufficient to induce melanoma in vivo. In this present study, the transforming properties of Grm1 in two cultured immortalized melanocytes were investigated. We showed that, in contrast to parental melanocytes, these Grm1-clones have lost their requirement of TPA supplement for proliferation and have acquired the ability to form colonies in semi-solid medium. Xenografts of these cells formed robust tumors in both immunodeficient nude and syngeneic mice with a short latency (3-5 days). The malignancy of these cells was demonstrated by angiogenesis and invasion to the muscle and the intestine. The requirement of Grm1 expression for the maintenance of transformation was demonstrated by an inducible siRNA system. Induction of expression of siRNA for Grm1 reduced the number of proliferating/viable cells in vitro and suppressed in vivo xenografted tumor growth in comparison with control. Taken together, these results showed that expression of exogeneously introduced Grm1 is sufficient to induce full transformation of immortalized melanocytes.

摘要

此前,我们报道了一种转基因小鼠品系TG-3,其会100%自发发生黑色素瘤。我们证明,黑素细胞中Grm1的异位表达足以在体内诱导黑色素瘤。在本研究中,我们研究了Grm1在两种永生化黑素细胞系中的转化特性。我们发现,与亲代黑素细胞相比,这些Grm1克隆在增殖时不再需要添加佛波酯(TPA),并且获得了在半固体培养基中形成集落的能力。这些细胞的异种移植在免疫缺陷的裸鼠和同基因小鼠中均能迅速形成肿瘤,潜伏期较短(3-5天)。这些细胞的恶性特征表现为血管生成以及侵袭肌肉和肠道。通过诱导型siRNA系统证明了维持转化需要Grm1的表达。与对照相比,诱导表达针对Grm1的siRNA可减少体外增殖/存活细胞的数量,并抑制体内异种移植肿瘤的生长。综上所述,这些结果表明,外源导入的Grm1的表达足以诱导永生化黑素细胞的完全转化。

相似文献

1
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.
Pigment Cell Melanoma Res. 2008 Jun;21(3):368-78. doi: 10.1111/j.1755-148X.2008.00452.x. Epub 2008 Apr 23.
2
Functional effects of GRM1 suppression in human melanoma cells.
Mol Cancer Res. 2012 Nov;10(11):1440-50. doi: 10.1158/1541-7786.MCR-12-0158. Epub 2012 Jul 13.
3
AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).
Pigment Cell Melanoma Res. 2010 Feb;23(1):103-11. doi: 10.1111/j.1755-148X.2009.00648.x. Epub 2009 Oct 20.
4
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Cancer Res. 2007 Mar 1;67(5):2298-305. doi: 10.1158/0008-5472.CAN-06-3665.
5
Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.
Breast Cancer Res Treat. 2015 May;151(1):57-73. doi: 10.1007/s10549-015-3365-8. Epub 2015 Apr 10.
6
Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes.
Neuropharmacology. 2005;49 Suppl 1:70-9. doi: 10.1016/j.neuropharm.2005.05.018.
8
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
Cell Signal. 2006 Aug;18(8):1279-86. doi: 10.1016/j.cellsig.2005.10.012. Epub 2005 Nov 21.
9
Glutamatergic signaling in cellular transformation.
Pigment Cell Melanoma Res. 2012 May;25(3):331-42. doi: 10.1111/j.1755-148X.2012.00983.x. Epub 2012 Feb 20.

引用本文的文献

1
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.
Cancers (Basel). 2024 Apr 19;16(8):1571. doi: 10.3390/cancers16081571.
3
Overview of current melanoma therapies.
Pigment Cell Melanoma Res. 2024 Sep;37(5):562-568. doi: 10.1111/pcmr.13154. Epub 2023 Dec 8.
4
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy Study.
J Invest Dermatol. 2023 Oct;143(10):2007-2018.e6. doi: 10.1016/j.jid.2023.03.1664. Epub 2023 Mar 29.
6
From simplicity to complexity in current melanoma models.
Exp Dermatol. 2022 Dec;31(12):1818-1836. doi: 10.1111/exd.14675. Epub 2022 Oct 5.
7
Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.
Cancers (Basel). 2022 Jan 29;14(3):706. doi: 10.3390/cancers14030706.
8
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity.
Immunity. 2021 Oct 12;54(10):2354-2371.e8. doi: 10.1016/j.immuni.2021.09.005. Epub 2021 Oct 5.
9
Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Cancers (Basel). 2021 Jul 31;13(15):3874. doi: 10.3390/cancers13153874.
10
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.
Front Oncol. 2021 Feb 4;10:626129. doi: 10.3389/fonc.2020.626129. eCollection 2020.

本文引用的文献

1
Genetic analysis of the GRM1 gene in human melanoma susceptibility.
Eur J Hum Genet. 2007 Nov;15(11):1176-82. doi: 10.1038/sj.ejhg.5201887. Epub 2007 Jul 4.
3
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Cancer Res. 2007 Mar 1;67(5):2298-305. doi: 10.1158/0008-5472.CAN-06-3665.
4
Differential oncogenic potential of activated RAS isoforms in melanocytes.
Oncogene. 2007 Jul 5;26(31):4563-70. doi: 10.1038/sj.onc.1210239. Epub 2007 Feb 5.
5
Glutamate receptors on human melanocytes regulate the expression of MiTF.
Pigment Cell Res. 2006 Feb;19(1):58-67. doi: 10.1111/j.1600-0749.2005.00284.x.
6
Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
Cell Signal. 2006 Aug;18(8):1279-86. doi: 10.1016/j.cellsig.2005.10.012. Epub 2005 Nov 21.
7
NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth.
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15605-10. doi: 10.1073/pnas.0507679102. Epub 2005 Oct 17.
8
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.
Nat Genet. 2005 Oct;37(10):1047-54. doi: 10.1038/ng1634. Epub 2005 Sep 4.
9
One-week 96-well soft agar growth assay for cancer target validation.
Biotechniques. 2004 May;36(5):826-8, 830, 832-3. doi: 10.2144/04365ST07.
10
V599EB-RAF is an oncogene in melanocytes.
Cancer Res. 2004 Apr 1;64(7):2338-42. doi: 10.1158/0008-5472.can-03-3433.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验